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Abstract (150/150 words)	
Over the last decade, genome-wide association studies (GWAS) of psychiatric disorders have 
identified numerous significant loci. Whereas these studies initially depended on cohorts 
ascertained for specific disorders, there has been a gradual shift in the ascertainment strategy 
towards population-based cohorts (PBCs) for which both genotype and heterogeneous 
phenotypic information are available. One of the advantages of PBCs is that, in addition to 
clinical diagnoses and various proxies for diagnoses (“minimal phenotyping”), many of them 
also provide non-clinical phenotypes, including putative endophenotypes, that can be used to 
study domains of normal function in addition to, or instead of, clinical diagnoses. By studying 
endophenotypes it is possible to both dissect psychiatric disorders (“splitting”) and to combine 
multiple phenotypes (“clumping”), which can either reinforce or challenge traditional diagnostic 
categories. Such endophenotypes may also permit a deeper exploration of the neurobiology of 
psychiatric disorders. A coordinated effort to fully exploit the potential of endophenotypes is 
overdue.
For decades, the field of psychiatric genetics largely failed to identify replicable associations. 
A watershed moment occurred several years ago, with the first successful genome-wide 
association study (GWAS) for schizophrenia1. Since then, numerous GWAS for other psychiatric 
disorders have enjoyed similar success2. It has now become clear that very large sample sizes are 
needed because common psychiatric diseases are highly polygenic, perhaps even omnigenic3. 
Whereas the initial focus was on identifying individual genes and loci4, larger samples and 
polygenic methodologies have emphasized the importance and utility of sub-genomewide 
significant signals. In addition, recent evidence has confirmed an important role for rare and even 
de novo variants5–8. Well-powered case control studies have been essential to understand the 
genetics of psychiatric disorders, and ascertaining more cases and controls will certainly yield more 
genome-wide significant associations. But is that all that we should be doing?	
In recent psychiatric genetics studies, the largest and most rapid growth in sample size has 
not come from ramping up ascertainment of cases, but rather from utilizing increasingly abundant 
population-based cohorts (PBCs), such as UK Biobank (UKB), Million Veterans Project (MVP), and 
cohorts from genetics-focused companies such as deCode Genetics and 23andMe (Box 1). In 
some cases, PBCs have simply provided additional cases and controls. For example, the first 
successful GWAS for schizophrenia included cases and controls from deCode Genetics1. Much 
more recently, MVP has provided by far the largest cohorts for diseases such as alcohol use 
disorder (AUD)9, opiate use disorder (OUD)10, and post-traumatic stress disorder (PTSD)11 by using 
electronic health records as a source of phenotypic information12,13. Moreover, self-reported clinical 
diagnosis collected by 23andMe (e.g. “Have you ever been diagnosed with clinical depression?”) 
provided the majority of the data for a recent GWAS for MDD14. Self-reported case status was also 
used for replication in a recent GWAS of ADHD15. Finally, both UKB and 23andMe have been rich 
sources of non-disease phenotypes, such as neuroticism16, insomnia17 and risk tolerance18, which 
are continuously distributed and can therefore be measured in the general population but are still 
relevant to multiple psychiatric disorders (Figure 1). In this perspective, we will explore how PBCs 
are changing ascertainment and phenotyping strategies in ways that create new challenges but 
may also provide opportunities for a deeper understanding of psychiatric disorders.	
Advantages and caveats of population-based cohorts 	
Whereas genetic studies have traditionally ascertained cases for a particular disorder, PBCs 
may contain individuals who can serve as cases (and controls) for numerous different disorders. 
However, several limitations need to be considered. The ascertainment of PBCs, while not focused 
on a specific diagnosis, is never random and therefore does not represent the general population19. 
For example, 23andMe and UKB20 research participants are more highly educated and have higher 
SES than the general population. In addition, similar to traditionally ascertained genetic cohorts, 
current PBCs are overwhelmingly made up of individuals of European ancestry; although MVP is a 
notable exception21. Another limitation of PBCs is that certain disorders are underrepresented; for 
example, in UKB, the frequency of schizophrenia (524 research participants with ICD codes for 
schizophrenia out of 410,293) is lower than the general population22, perhaps reflecting the lower 
rate at which schizophrenia patients volunteered to participate in such a rigorous study. The age of 
subjects in PBCs is another potential limitation. For example, the use of diagnoses for childhood 
onset disorders like ADHD and autism have changed dramatically over the past few decades, 
meaning that older subjects will have a lower than expected prevalence of these diagnoses. In 
addition, the prevalence of environmental exposures (e.g. smoking), which modulate the prevalence 
of many traits and diseases, have changed over time, which may confound various genetic studies. 
Lastly, privacy and intellectual property concerns restrict the sharing of raw data and even the 
results obtained from some PBCs, these restrictions impede data sharing. Despite these limitations, 
PBCs are attractive because they are economical, offer the potential to dramatically increase 
sample size, provide a much greater diversity of phenotypes, and lend themselves to innovative 
study designs. 	
In some PBCs, clinical diagnoses are not available. However, self-reported clinical 
diagnoses may be available. For obvious reasons, these self-reported diagnoses must be 
interpreted with caution; however, the strength of the genetic correlation between gold-standard 
diagnoses and self-reported diagnoses helps to address this concern. For example, self-reported 
MDD and clinician assigned MDD showed a robust genetic correlation (rg = 0.86)14. In other cases, 
self-reported diagnoses are unavailable, but screening tools can be used to approximate 
diagnoses. For example, scores from the Alcohol Use Disorder Identification Test (AUDIT23), which 
is as a screening tool for AUD, were available in research participants from 23andMe and UKB. 
Sanchez-Roige et al24 found that when AUDIT scores were converted into a case control 
phenotype, they were highly genetically correlated with AUD (rg = 0.82)25. These examples 
demonstrate that, even when clinical diagnoses are not available, there is still significant value in 
using self-reported information from PBCs for genetic studies of psychiatric disorders.	
Minimal phenotyping and endophenotypes for refining psychiatric genetics 	
In general, there is a tradeoff between phenotyping depth and sample size (Figure 2). The 
quest for larger sample sizes has led to the adoption of “minimal phenotyping” where a complex 
disease or trait may be reduced to a single yes or no question. Minimal phenotyping is sometimes 
criticized because it implicitly assumes that minimal phenotypes are merely noisy measurements of 
a true underlying phenotype26. Cai et al26 sought to empirically examine this question by considering 
both self-reported diagnosis of MDD and clinician measurements of the cardinal symptoms of MDD 
and found that minimal phenotyping yielded a qualitatively different trait. Another empirical 
examination of minimal phenotyping used a multivariate framework (Genomic SEM27) to evaluate 
several psychiatric disorders and self-report measures of their cardinal symptoms28. That study 
identified large genetic correlations between some disorders and symptom pairs (e.g. MDD, 
depressive symptoms), but very modest genetic correlations between other pairs (e.g. bipolar 
disorder and manic symptoms; schizophrenia and psychotic symptoms). Despite these limitations, 
robust genetic signals -- of something -- can be obtained using minimal phenotyping; how useful 
these signals will be for understanding the pathophysiology of psychiatric disorders is a matter of 
ongoing debate, but when large, minimally phenotyped datasets exist, it seems natural that they 
should be analyzed. 	
Regardless of whether diagnoses are made by an expert clinician, a structured interview, or 
self-report, there is a broader question about whether or not the current diagnostic categories are 
optimal for genetic research, given that the DSM was never intended to be a research tool. A recent 
review summarized this issue with the memorable phrase “our genes don’t seem to have read the 
DSM”29. Initiatives such as the National Institute of Mental Health (NIMH) Research Domain Criteria 
(RDoC)30 and Hierarchical Taxonomy of Psychopathology (HiTOP31) provide new ways of 
classifying psychiatric disorders based on dimensions of observable behavioral and neurobiological 
measures, rather than diagnostic categories. These approaches have not been universally 
accepted32. Even before RDoC, there was widespread enthusiasm for genetic studies of 
endophenotypes (Box 2); however, studies of endophenotypes flourished in the era of candidate 
genes, when the necessity of large sample sizes was not generally understood. This may have 
fostered undue skepticism about the utility of endophenotypes for genetic research. 	
There are several recent examples of adequately powered genome-wide (rather than 
candidate gene) association studies of endophenotypes. For example, impulsivity, which has been 
defined as “actions which are poorly conceived, prematurely expressed, unduly risky or 
inappropriate to the situation, and that often result is undesirable consequences”33 appears to meet 
the criteria for an endophenotype for multiple psychiatric disorders, including attention-
deficit/hyperactivity disorder (ADHD) and several substance use disorders (SUD). Numerous 
genetic studies have now shown that various measures of impulsivity34–36 and sensation seeking39 
are heritable and that they are genetically correlated with both ADHD and various substance use 
related traits34,35. In addition, risk tolerance (“would you describe yourself as someone who takes 
risks?”), which has also been proposed as an endophenotype for both ADHD and substance use 
disorders, was recently measured in over one million individuals (primarily from UKB and 
23andMe18). Although risk tolerance was measured using a minimal phenotype (a single vaguely 
worded question), risk tolerance was clearly heritable and the large sample size allowed 
identification of 124 genome-wide significant loci18. Some of these loci have also been implicated in 
clinically defined traits25. Furthermore, risk tolerance was positively genetically correlated (rg > 0.3) 
with numerous clinically relevant traits (e.g. ADHD, SUD). This study illustrates the power of 
minimal phenotyping to capture an endophenotype that informs complex disorders and also 
conforms to the RDoC framework. In a third example, Ibrahim-Verbaas et al37 performed a GWAS 
for executive function, which can be considered an endophenotype for multiple psychiatric traits. 
Intriguingly, GWAS of sensation seeking35, risk tolerance18 and executive function37 all identified a 
locus that included the gene CAMD2, which was subsequently associated with AUD9. Whether all of 
these associations are due to a single locus or multiple loci is far from clear38, but the index SNPs 
for these studies are typically co-inherited (LD is ~0.9), consistent with a single causal locus. 	
Another example of an intriguing endophenotype is self-reported loneliness (e.g. “Do you 
often feel lonely?”), which is a strong predictor of mortality and life satisfaction and appears to 
precede the onset of MDD39. Several recent GWAS of loneliness40–42 have identified several 
significant loci and shown that a genetic predisposition to loneliness is genetically correlated with 
psychiatric, cardiovascular, and metabolic disorders. By assigning polygenic risk scores to 
individuals for whom electronic medical records were also available, Dennis et al43 showed that 
genetic liability for loneliness increased the risk to develop coronary artery disease more robustly 
than MDD. Thus, loneliness is an endophenotype that is relevant to both MDD and a variety of 
somatic disorders. 	
While some endophenotypes may be amenable to minimal phenotyping, others represent 
extremely deep and rich data types. For example, by passively collecting data from wearable 
devices and smartphones, certain endophenotypes relevant to psychiatric disorders can be 
measured44. In a recent GWAS of circadian rhythm, wearable devices were used to gather objective 
measures of sleep timing, duration and quality45. More recently, structural connectivity from fMRI 
was proposed as endophenotype for IQ46. Elliott et al47 used 3,144 functional and structural brain 
imaging phenotypes from UKB to conduct GWAS that identified novel associations that included 
genes relevant to brain development, pathway signaling and plasticity.  
A path forward for researching endophenotypes 
Despite compelling examples like these, there has not been a coordinated effort to define 
and explore the endophenotype space. Whereas psychiatric disorders require ascertainment of 
cases and controls, endophenotypes are continuous and could therefore be measured at scale in 
PBCs (Figure 1). The Psychiatric Genomics Consortium (PGC) has subdivided psychiatric genetic 
studies into working groups for each major diagnostic category; in contrast, while individual groups 
have been formed around specific projects (e.g. the Social Science Genetic Association 
Consortium, https://www.thessgac.org; the Cognitive Genomics Consortium), there is no 
coordinated effort to establish a similar set of working groups focused on GWAS of 
endophenotypes or RDoC traits; however, we feel such an effort is overdue. 	
The approach we are proposing will be orthogonal to the efforts of the PGC because RDoC 
traits and endophenotypes “split” diagnostic categories into discrete units of analysis. The SUD field 
provides a good example of how a complex disorder can be split into smaller, more biologically 
meaningful units. SUD develop in accordance with an obligate longitudinal pattern: drug 
experimentation → regular use → harmful use → transition to compulsive use → quit attempts → 
relapse (Figure 3a). Approaching SUD with a case control framework merges the genetic liability 
for each of these stages into a single phenotype, obscuring the distinct biological factors relevant at 
each stage. In contrast, several recent projects have focused on individual stages of SUD, which 
can help to address this limitation. For example, GSCAN used data from almost 1 million individuals 
to examine a number of SUD-related traits, including smoking initiation48. In another example, the 
genetic relationship between alcohol consumption and AUD was explored using the AUDIT, a 10-
item questionnaire that measures alcohol use and misuse24. By dissecting the genetic contribution 
for alcohol consumption (first 3 items) vs problematic use (final 7 items), Sanchez-Roige et al24 and 
Kranzler et al9 showed a surprisingly low correlation between alcohol consumption and AUD 
(rg=0.33 and 0.52, respectively); however, the correlation between problematic alcohol use and 
AUD was stronger (rg=0.63)24.	
Even when the temporal stages of a psychiatric disorder cannot be so clearly delineated, it 
can be helpful to split diagnoses into endophenotypes that are associated with the disease of 
interest. For example, a recent GWAS of insomnia17, which is a core symptom of multiple 
psychiatric disorders and a DSM criterion for MDD, identified 202 loci and showed strong genetic 
correlations with MDD (rg=0.5) and several other psychiatric conditions . Similarly, neuroticism, 
which shares a common genetic basis with MDD but can be more easily measured, could serve as 
a clinical stratifying factor for antidepressant actions16. However, it can be difficult to determine what 
level of dissection is required; a recent study suggested that neuroticism reflected two genetic 
dimensions, one capturing depressed affect, and another capturing worry49. Another example 
comes from several GWAS of impulsive personality35, which has been proposed as an 
endophenotype for several psychiatric disorders including ADHD. The UPPS-P is a self-reported 
questionnaire that measures 5 different aspects of impulsive personality. Only two of those five 
were significantly associated with ADHD; in contrast, all three subscales of BIS-11, which is another 
impulsive personality questionnaire, were significantly associated with ADHD35. These examples 
illustrate how disease phenotypes can be dissected into component parts. Nonetheless, despite the 
original claim that endophenotypes would have a simpler genetic architecture50, all studies 
conducted to date have shown that both disease diagnoses and endophenotypes are highly 
polygenic.	
Once the traits that reflect domains of normal function have been measured (“split”) in 
genotyped cohorts, it becomes possible to explore their empirical relationships with one another 
(“clumping”) beyond those that are already defined by traditional psychiatric nosology (see Figure 
3b). Genomic SEM27 and related techniques are now being used in a number of such efforts. 
Luningham et al51 used genomic SEM to test multiple models of psychopathology among fourteen 
psychiatric disorders and related traits. They identified three factors (namely Externalizing, 
Internalizing, and Thought Problems), and an uncorrelated Neurodevelopmental Disorders factor. 
These factors showed distinct patterns of genetic correlations and accounted for substantial genetic 
variance. These empirically identified clusters may provide better targets for GWAS than individual 
disorders. In another example, Baselmans et al52 showed that it was possible to increase power by 
using Genomic SEM to integrate multiple traits (life satisfaction, positive affect, neuroticism, 
depressive symptoms) into a measure of “well-being spectrum”. By aggregating data from different 
sources of correlated traits, they reached a sample size of over 2.3 million individuals, which 
allowed them to identify 304 independent signals associated with well-being; a similar analysis 
suggested a two factor model that distinguishes “lower end” and “higher end” well-being factors53. In 
a third example, Thorp et al54 used Genomic SEM to identify two factors, which they referred to as 
“psychological” and “somatic” from the 9-item Patient Health Questionnaire (PHQ-9). Recently, 
several related methods have been developed (e.g. reverse GWAS, RGWAS55 and BUHMBOX56). 
Using RGWAS, Dahl et al55 proposed a stress subtype in MDD, and identified three novel subtypes 
of metabolic traits. Using BUHMBOX (Breaking Up Heterogeneous Mixture Based On Cross-locus 
correlations), Han et al56 found that seropositive and seronegative rheumatoid arthritis could be 
subdivided to form a new subgroup within seronegative-like cases. Conversely, they identified a 
genetic correlation between MDD and SCZ, but there was no evidence that this correlation was due 
to subgroup heterogeneity. 	
Clumping has been used to test the hypothesis, originally suggested by twin studies, that 
psychiatric disorders share a single common genetic factor (the “p-factor”)57. One of the earliest 
studies to use GWAS data to test this hypothesis showed that SNPs associated with schizophrenia 
were also associated with bipolar disorder58. Specific genes have been identified that confer risk for 
multiple psychiatric disorders (e.g. CACNA1C59–61). Evidence that the risk for substance abuse is 
shared across multiple substances (e.g. alcohol, tobacco48) is also consistent with earlier results 
from twin studies showing both substance-specific and substance-independent genetic risk. An 
example of this genetic overlap is the gene CADM2, which has been associated several substances 
(alcohol use24,62, tobacco and cannabis initiation63) and risky behavior18,35. Joint analysis of 
correlated traits may outperform that of single phenotypes and allows the possibility to disentangle 
genetic effects that are specific to each trait from those that capture a latent construct (Figure 3b).	
Clumping can also lead to new splits. For example, Bansal et al64 used GWAS results from 
two correlated traits: schizophrenia (a disorder) and educational attainment (a continuously 
distributed non-disorder trait) to propose two distinct etiologies of schizophrenia, one that 
resembled bipolar disorder and was characterized by high education, and another that reflected a 
cognitive disorder and was independent of education. Studies like this one provide greater flexibility 
to explore the phenotypic space, which can lead to novel insights and challenge established 
nosologies. 	
The utility of endophenotypes for translation to cellular and animal models 	
Throughout this perspective, we have alluded to GWAS producing novel biological insights; 
however GWAS have numerous limitations65 and do not themselves produce actionable new 
knowledge. The influence of locus on a phenotype may be due to a coding difference or a 
regulatory difference. The former can be directly identified from sequence data (although the 
interpretation of sequence variants is still challenging), whereas regulatory polymorphisms are 
typically identified by using complementary data from GTEx66, PsychENCODE 
(resource.psychencode.org), CommonMind 
(https://www.synapse.org/#!Synapse:syn2759792/tables/) and Brainspan 
(http://www.brainspan.org/); or protein QTLs (pQTLs; e.g. 67). Once identified, the protein products 
of such genes can be intensively studies and evaluated as possible drug targets68. Another way to 
follow up on GWAS results is to use cellular and animal models. However, these approaches have 
been challenging because psychiatric diseases cannot be recapitulated in cells or non-human 
animals. On the contrary, certain endophenotypes can be more readily modeled in animals, which 
provides an opportunity to evaluate the role of genes identified by GWAS at the molecular, cellular 
and circuit level56. Individual genes can also be manipulated in animal models by using viral vectors, 
genetically engineered null alleles (knock outs), over expression alleles, conditional alleles or 
knockins of humanized alleles. These approaches provide a gene-by-gene approach to translation -
- what is still lacking are robust methods for examining the polygenic nature of complex traits in 
animal models. In contrast, methods for using human-derived cellular models to examine the 
polygenic signals obtained from GWAS are better established. The ability to more directly model 
endophenotypes in experimental model systems will be critical in extracting biological insights from 
GWAS and thus realizing the full potential of psychiatric genetic studies. 		
Conclusion	
Over the last 10 years, GWAS for psychiatric disorders have turned a corner and begun to 
identify numerous significant loci for all major psychiatric disorders. It is generally understood that 
larger samples will extend on these successes. In this perspective, we have considered additional 
study designs that go beyond disease diagnoses. Although they are not without limitations, PBC are 
quickly becoming the predominant ascertainment strategy. Direct-to-consumer genetic companies, 
which collectively account for millions of research participants (https://thednageek.com/dna-tests/), 
are the largest PBCs. Publicly funded PBC already account for millions of research participants and 
are linked to electronic health records and other rich data types (e.g. questionnaire data, imaging 
data, epigenetics). Unlike previous ascertainment strategies, PBC have provided adequate sample 
sizes for GWAS of endophenotypes. This has allowed for increasingly sophisticated study designs. 
These resources are already leading to neurobiological insights about the molecular, cellular and 
circuit underpinnings associated with psychiatric disorders that will facilitate the translation of 
psychiatric genetic insights to other fields of neuroscience.	
Figure 1. Case control vs continuous phenotypes. Psychiatric disorders require ascertainment 
of cases and controls and because of their binary nature they do capture variability within the two 
classes, a problem that is addressed by a continuous phenotype.	
	
Figure 2. The trade-off between phenotyping depth and sample size. Deep phenotyping is 
more expensive and time consuming; therefore, when the available budget is fixed, greater 
phenotyping depth comes at the expense of sample size. In contrast, scalable phenotyping 
strategies, which are more commonly used in PBCs, allow for larger sample sizes. 	
	
 
Figure 3. Splitting vs clumping. Psychiatric disorders can be further dissected or “split” into 
discrete units of analysis; for example, SUDs can be split into smaller, more biologically meaningful 
traits, that manifest into an obligate longitudinal pattern: drug experimentation → regular use → 
harmful use → transition to compulsive use → quit attempts → relapse. The empirical correlations 
among these traits can be examined (“clumping”) beyond those that are already defined by 
traditional psychiatric nosology. Recently, The Externalizing Consortium has sought to analyze the 
genetic correlations between different traits from the externalizing spectrum (https://osf.io/xkv36/), 
including sexual and drug-related phenotypes, impulsivity, and attention-deficit/hyperactivity 
disorder, with the goal of identifying loci involved in a shared underlying liability to externalizing 
versus genes unique to specific phenotypes. 
	
Box 1. Some of the major population-based cohorts in psychiatric genetics  
• UK Biobank (UKB): prospective cohort with rich phenotypic information including 
biological, lifestyle, biomarkers, and imaging data and genetic information from 
approximately 500,000 volunteer research participants across the United Kingdom. 
Participants are predominantly of European ancestry, middle age and older69, and with 
higher socioeconomic backgrounds than the general population70. 
• Million Veterans Project (MVP): observational cohort study in the Department of 
Veterans Affairs (VA) health care system containing deep phenotyping, including the 
VA electronic health records, and genotypes21. At the time of this writing more than 
450,000 individuals have already been genotyped. Most participants are male, with a 
mean age of 64. While the majority of the participants are of European ancestry, this 
cohort also contains significant numbers of individuals from other ancestral groups. 
• deCODE Genetics, Inc.: biopharmaceutical company based in Reykjavík, Iceland, funded in 
1996 to study genetic risk factors for several diseases (https://www.decode.com). deCODE 
contains genotypic and medical data from >160,000 volunteer participants, comprising 
about half of the adult population in Iceland.  
• 23andMe, Inc: direct-to-consumer genetic company with over 5 million genotyped 
individuals71; research participants tend to have higher education levels and 
socioeconomic status than the general population (e.g. 34).  
 
	
Box 2: criteria for a trait to be considered an endophenotype, as defined by50	
1. The endophenotype is associated with illness in the population [genetic correlation].  	
2. The endophenotype is heritable. 	
3. The endophenotype is primarily state-independent (manifests in an individual whether or not 
illness is active). 	
4. Within families, endophenotype and illness co-segregate.	
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